Long being regarded as an unattractive market, vaccines have re-emerged as
successful growth driver for Big Pharma. The launch and rapid uptake of novel,
high-price products such as Wyeth' s Prevnar or Merck & Co' s Gardasil, along
with the emergence of novel vaccine technologies and favourable legislation
have brought vaccines back into the main focus of pharmaceutical and biotech
companies.
Features and benefits
Market overview with current market assessment in terms of leading
players, brands and geographies
In-depth analyses of the leading 5 players' portfolios, R&D pipelines,
sales trends, geographic spread, licensing patterns and strategic outlook
Discussion of key developments shaping the sector: new technologies,
indications and geographies
Snapshot profiles of second tier companies in the sector
Highlights
Driven by its increasing commercial potential, the vaccines sector has been
subject to significant consolidation over the last 5 years. While some of this
recent activity has paved the way for newer market entrants, at the same time,
established players have sought to diversify their portfolios through new
acquisitions.
Key opportunities for vaccine manufacturers lie in the exploitation of novel
targets with a high unmet need. Development of candidates for these
indications can be facilitated by novel technologies, such as adjuvants,
alternative production and delivery techniques, and novel approaches in
antigen design.
Faced with limited growth prospects in the western markets, companies are
increasingly turning towards emerging countries. The higher disease burden,
greater medical unmet needs combined with rapid economic growth, a growing
affluent middle class and private sector in these countries represents
significant potential for market expansion.
Your key questions answered
Get a comprehensive, insightful commercial overview of the vaccines market
Learn about the strategies of the Big 5 players, their strengths,
weaknesses, similarities and differences
Gain insight into the future directions and growing strategic importance
of vaccines for Big Pharma
Table of Contents
Table of Contents
OVERVIEW
Catalyst
Summary
About Datamonitor healthcare
About the Vaccines & Infectious Diseases Pharmaceutical Analysis Team
EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor insight into the vaccines market
Related reports
MARKET OVERVIEW
Summary
Vaccines have emerged as key revenue drivers
Current market assessment
Snapshot of key new entrants
Snapshot of other vaccines players
Opportunities and threats
GlaxoSmithKline
Summary
Strategic overview
Portfolio analysis
Pipeline analysis
Deals and alliances
Strategic outlook
Sanofi Pasteur
Summary
Strategic overview
Portfolio analysis
Pipeline analysis
Deals and alliances
Strategic outlook
Merck & Co.
Summary
Strategic overview
Portfolio analysis
Pipeline analysis
Deals and alliances
Strategic outlook
Novartis
Summary
Strategic overview
Portfolio analysis
Pipeline analysis
Deals and alliances
Strategic outlook
Pfizer
Summary
Strategic overview
Portfolio analysis
Pipeline analysis
Strategic outlook
APPENDIX A
Contributing experts
Conferences attended
Report methodology
About Datamonitor
Infectious Diseases Vaccine Market Overview published by Datamonitor in October 25, 2010. This report consists of Pages: 196, Slides: 30 and the price starts from US $ 15200.
